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Abstract
Background: B7-H4, a co-inhibitory molecule of the B7 family, can restrain T cell proliferation, cytokine
secretion and the development of cytotoxicity. B7-H4 is expressed in tumor tissues at a higher level than
in normal tissues, and has a potential effect to protect tumors from anti-tumor immune responses. This
case-control study was carried out to determine the potential influences of B7-H4 gene polymorphisms
on the susceptibility and progression of breast cancer in Han women of Northeast China.
Methods: We genotyped three B7-H4 variants (rs10754339, rs10801935 and rs3738414) and tagged all
common haplotypes (frequency greater than or equal to 1%) in a Chinese population consisting of 500
breast cancer cases and 504 control individuals matched for age. Polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) technique was used to determine the genotypes.
Results: Our data indicated that, compared with the common genotype and allele of each SNP, the
rs10754339 AG genotype and G allele showed a significantly increased risk of breast cancer (OR = 1.455,
95% CI 1.119-1.892; OR = 1.325, 95% CI 1.073-1.637, respectively). The rs10801935 CC genotype, the
rs3738414 AA genotype and the rs3738414 A allele were associated with a significantly decreased risk of
breast cancer (OR = 0.328, 95% CI 0.145-0.739; OR = 0.412, 95% CI 0.203-0.835; OR = 0.698, 95% CI
0.564-0.864, respectively). Additionally, the rs10754339 GG genotype was significantly associated with
lymph node metastasis and PR status, and the G allele and the AG genotype were respectively associated
with lymph node metastasis and ER status. In haplotype analysis, we observed that compared with the
AAG haplotype, the AAA haplotype showed a significantly decreased risk of breast cancer (OR = 0.689,
95% CI 0.539-0.881), but the GAG haplotype was associated with a significantly increased risk of breast
cancer (OR = 1.511, 95% CI 1.125-2.031). And the AAA and the GCG haplotypes also respectively have
significant influences on tumor size and ER status.
Conclusion: These results suggest that B7-H4 gene polymorphism may contribute to the sporadic breast
cancer risk and prognosis in Chinese Han women.
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Background
Breast cancer is one of the most common malignant
tumors in females, and its etiology as well as prognosis is
extremely complex. The immune system, which plays an
important role of immune surveillance in finding and
eliminating cancer cells, can influence the development
and growth of breast cancer. The central regulator of anti-
tumor immune response is mediated by T lymphocyte,
whose activation is regulated by co-stimulatory mole-
cules, especially the receptors and ligands in B7-CD28
family [1,2].
B7-H4 is a recently identified member of B7 family, and
conducts a co-inhibitory signal to T cell activation, which
can restrain T cell proliferation, cytokine secretion and the
development of cytotoxicity [3-5]. Experiments in vitro
show that B7-H4 inhibits T cell activation through
restraining IL-2 production and arresting cell cycles of
both CD4+ and CD8+ T cell, and experiments in vivo also
support the function of B7-H4 as an inhibitor to T cell
mediated immunity [3-5]. B7-H4  mRNA transcriptions
are detected extensively in spleen, lung, thymus and other
normal tissues, but the proteins are not detectable in these
tissues [3]. In contrast, high levels of B7-H4 protein are
expressed in most kinds of tumors, such as breast cancer
[6,7], ovarian cancer [7,8], lung cancer [8,9] and renal cell
carcinoma [10]. Previous reports [6,7,11] showed that the
high expression of B7-H4 protein in breast cancer
decreased the number of tumor infiltrating lymphocytes
(TILs) and prevented tumor cells from apoptosis. There-
fore, the B7-H4 protein is a negative regulator of the anti-
tumor immune response and may play an important role
in breast cancer. And in our research, we investigated the
association between B7-H4 gene polymorphisms and the
risk of breast cancer.
The human B7-H4  gene is located on chromosome
1p11.1, and consists of six exons and five introns [8].
There are two types of B7-H4 mRNA transcriptions which
are ~2.0 kb and ~800 bp. The larger transcription is dom-
inant, and differs from the small one that has part of 3'-
untranslating region (UTR) spliced. It is likely that the dif-
ference of 3'-UTR between the two transcripts affects the
efficiency of B7-H4 protein synthesis [8]. In addition, B7-
H4 mRNA transcription is inconsistent with its protein
expression [3], indicating that B7-H4 expression is tightly
controlled at the translational level in peripheral tissues.
It has been pointed out that UTRs and introns, especially
intron1, can modulate gene expression at many levels,
such as the production of stable mRNA, the translational
efficiency, the rate of mRNA decay, and so on [12-14]. In
our study, we detected three polymorphic sites in UTRs
and intron1, and established the association between B7-
H4 gene polymorphisms and the risk of breast cancer in a
Chinese Han population of Northeast China.
Methods
Subjects
The blood samples of the cases in our study were provided
by the Department of Abdominal Surgery (The Third Affil-
iated Hospital of Harbin Medical University). They were
collected from 500 Chinese women with sporadic breast
cancer (mean age ± SD: 46.2 ± 7.6 years), and medical
records were used to further confirm their pathological
and clinical information of diagnoses (table 1). The blood
samples of controls were contributed by 504 healthy
women volunteers with matched ages who were from the
same district (mean age ± SD: 43.0 ± 7.2 years). They were
all selected randomly without any history of personal and
familial malignancy or autoimmune diseases. All of the
cases and healthy controls were recruited from Hei-
longjiang province of China during 2007 and 2008.
Before the beginning of this study, ethical board approval
from the Third Affiliated Hospital of Harbin Medical Uni-
versity was obtained, and each of the cases and controls
signed the written informed consent.
SNP selection and genotype analysis
Using Pupasview software [15], we found that
rs10754339 in 3'-UTR, and rs3738414 in 5'-UTR are
located on exonic splicing enhancers (ESEs), which may
influence splicing of the primary transcript with produc-
tion of stable mRNAs [16]. We also found that
rs10801935 in intron1 may cause the alteration of the
pre-mRNA secondary structure as predicted by RNAstruc-
ture 4.5 software [17]. Therefore, we detected these three
potential functional single nuclear polymorphisms
(SNPs) (rs10754339, rs10801935 and rs3738414) to
investigate their relevance to breast cancer in a Chinese
Han population of Northeast China.
Table 1: Clinicopathologic features of breast cancer cases 
(n = 500)
Feature No. of cases (%)
Tumor type IDC 426 (85.2)
DCIS 29 (5.8)
Other 45 (9.0)
Tumor size (cm) TZ ≤ 21 8 1  ( 3 6 . 2 )
2<TZ ≤ 52 1 9  ( 4 3 . 8 )
TZ>5 26 (5.2)
Missing 74 (14.8)
LN involvement Positive 220 (44.0)
Negative 280 (56.0)
ER Positive 241 (48.2)
Negative 180 (36.0)
Missing 79 (15.8)
PR Positive 320 (64.0)
Negative 99 (19.8)
Missing 81 (16.2)
Abbreviations: DCIS = ductal carcinoma in situ; ER = estrogen 
receptor; IDC = infiltrative ductal carcinoma; LN = lymph node; PR = 
progesterone receptor; TZ = tumor size.BMC Cancer 2009, 9:394 http://www.biomedcentral.com/1471-2407/9/394
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Genomic DNA was extracted from 5 ml frozen whole
blood with the Universal Genomic DNA Extraction Kit
Ver. 3.0 (TaKaRa, Japan), following the manufacturer's
protocol. Then, through a PCR-RFLP assay, we deter-
mined the dimorphism of rs10754339, rs10801935 and
rs3738414. The desired fragment was amplified by PCR
with a Biometra T-Gradient Thermoblock (Biometra, Göt-
tingen, Germany) in a reaction mixture of 25 μl solution
containing 0.3 μg of genomic DNA template, 1.25 U of
Taq DNA polymerase with 10×PCR buffer (Mg2+ plus)
and dNTPs contained in the kit (TaKaRa, Japan), and 0.1
μl of each primer (Invitrogen, China). PCR products were
digested with restriction enzymes (NEB, UK) according to
the manufacturer's description, and were analyzed with
2.0% agarose gel electrophoresis. Primer sequences of
each SNPs were rs10754339 (F: 5'-TCCTATGGGTCTGT-
CAATG-3'; R: 5'-GCTGCTAAACTCAAAGGC-3'),
rs10801935 (F: 5'-TAGTGGCGGTACAATAGC-3'; R: 5'-
AGTGCCTCTGTTTCTTCC-3'), and rs3738414 (F: 5'-AAA-
GACCTCACTGCTGTTCC-3'; R: 5'-CCACAGTCAGGAG-
GAAAGTC-3'). Annealing temperatures were rs10754339
(53.2°C), rs10801935 (55.6°C), and rs3738414
(55.6°C). The lengths of PCR products were rs10754339
(341 bp), rs10801935 (466 bp), and rs3738414 (419 bp).
And restriction enzymes were rs10754339 (MscI),
rs10801935 (SalI), and rs3738414 (BtsI) (please refer to
additional file 1). In order to ensure quality control of
genotyping results, we randomly selected 10% of the sam-
ples to direct sequencing, and the results were consistent
with the PCR-RFLP results.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) was tested using the
genotyping results of cases and controls respectively. The
polymorphisms were excluded if they deviated from HWE
(P < 0.05), as well as if the minor allele frequency was less
than 5% or the missing data was more than 25%. The fre-
quencies of allele and genotype were obtained by a simple
counting. Haploview 3.2 was used to reset haplotypes and
evaluate the frequencies in this case-control study. Chi-
square test was adopted using SPSS 13.0 software in order
to compare the different distributions within the allele,
genotype and haplotype frequencies in cases and controls
respectively, and the threshold for significance was P <
0.05. 10,000 permutations were run by Haploview pro-
gram to measure the P-value of allele frequencies after the
correction for multiple-testing bias. An odds ratio (OR)
and its 95% confidence interval (CI) were calculated using
SPSS 13.0 software to estimate the relative risk associated
with rare alleles for breast cancer.
Results
Genotype and allele frequencies
The B7-H4 gene polymorphisms were analyzed for 500
breast cancer cases and 504 healthy controls. Table 2 and
3 summarize respectively the genotype and the allele fre-
quencies of the B7-H4 gene polymorphisms in cases and
controls. For any of the three SNPs genotyped, there was
no deviation from Hardy-Weinberg equilibrium (P >
0.05), and no minor allele frequency less than 5% or
missing data more than 25%. The statistical results
showed that, the genotype and allele distributions in
rs10754339, rs10801935 and rs3738414 had statistically
significant differences (details are shown in table 2 and 3).
Compared with the AA genotype, the rs10754339 AG gen-
otype showed a significantly increased risk of breast can-
cer (OR = 1.455, 95% CI 1.119-1.892, P = 0.005). And the
rs10754339 G allele was associated with a significantly
increased risk of breast cancer compared with the A allele
(OR = 1.325, 95% CI 1.073-1.637, P = 0.009). The
rs10801935 CC genotype was associated with a signifi-
cantly decreased risk of breast cancer compared with the
AA genotype (OR = 0.328, 95% CI 0.145-0.739, P =
0.005). In rs3738414, the AA genotype showed a signifi-
cantly decreased risk of breast cancer compared with the
GG genotype (OR = 0.412, 95% CI 0.203-0.835, P =
Table 2: Genotype frequencies of B7-H4 polymorphisms in cases and controls
Genotype No. (%) OR
(95% CI)
PG l o b a l
P valuea
Cases (n = 500) Controls (n = 504)
rs10754339 AA 277 (55.40) 324 (64.29) Reference 0.016
AG 199 (39.80) 160 (31.75) 1.455 (1.119-1.892) 0.005
GG 24 (4.80) 20 (3.97) 1.404 (0.759-2.595) 0.278
rs10801935 AA 344 (68.80) 338 (67.06) Reference 0.017
AC 148 (29.60) 142 (28.17) 1.024 (0.778-1.348) 0.865
CC 8 (1.60) 24 (4.76) 0.328 (0.145-0.739) 0.005
rs3738414 GG 324 (64.80) 278 (55.16) Reference 0.003
AG 164 (32.80) 201 (39.88) 0.700 (0.539-0.909) 0.007
AA 12 (2.40) 25 (4.96) 0.412 (0.203-0.835) 0.011
aGlobal P-value was calculated using Chi-square test.
Abbreviations: CI = confidence interval; OR = odds ratio.BMC Cancer 2009, 9:394 http://www.biomedcentral.com/1471-2407/9/394
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0.011), and the A allele was associated with a significantly
decreased risk of breast cancer compared with the G allele
(OR = 0.698, 95% CI 0.564-0.864, P = 0.001). Further-
more, we corrected P-values for multiple testing, and sig-
nificant association was observed among the rs10754339
G allele and rs3738414 A allele (P = 0.036 and 0.003,
respectively).
In addition, we analyzed the correlation between the pol-
ymorphisms of B7-H4 gene and a series of clinicopatho-
logic features, including lymph node metastasis, tumor
size, and the statuses of estrogen receptor (ER) and pro-
gesterone receptor (PR). It was observed that in
rs10754339, compared with the AA genotypes, the GG
genotype was associated with a significantly increased risk
of lymph node metastasis (OR = 2.492, 95% CI 1.054-
5.894, P = 0.033), and the G allele showed a significantly
increased risk of lymph node metastasis compared with
the A allele (OR = 1.394, 95% CI 1.045-1.860, P = 0.024).
Compared with the rs10754339 AA genotype, the AG gen-
otype was associated with a significantly increased expres-
sion of ER (OR = 1.640 95% CI 1.092-2.464, P = 0.017),
and the GG genotype was associated with a decreased
expression of PR (OR = 0.367 95% CI 0.135-0.994, P =
0.041). However, no obvious correlation was revealed
between the genotype and allele frequencies and tumor
size.
Haplotype analysis
The association between B7-H4 SNPs and breast cancer
was further confirmed in our cohort by Haploview pro-
gram. Possible haplotypes were then reconstructed, of
which the ones with frequencies ≥ 1% are shown in table
4. The most frequently appeared haplotype in cases and
controls were AAG (rs10754339A, rs10801935A,
rs3738414G) (50.7%). And we found that compared with
the AAG haplotype, the AAA haplotype showed a signifi-
cantly decreased risk of breast cancer (OR = 0.689, 95% CI
0.539-0.881, P = 0.003), but the GAG haplotype was asso-
ciated with a significantly increased risk of breast cancer
(OR = 1.511, 95% CI 1.125-2.031, P = 0.006).
We also analyzed the association between the haplotypes
and the clinical features of cases. We found that the AAA
haplotype was significantly associated with tumor size (P
= 0.020), and compared with the AAG haplotype, the
GCG haplotype frequency was associated with a signifi-
cantly increased expression of ER (OR = 1.903, 95% CI
1.034-3.502, P = 0.036). However, no significant associa-
tion was obtained between haplotypes and either the
lymph node metastasis or the statuses of PR.
Discussion
Breast cancer is one of the polygenetic disorders with com-
plex inheritance patterns. Recently, the determination of
Table 3: Allele counts and frequencies of B7-H4 polymorphisms in cases and controls
Allele No. (%) OR
(95% CI)
P-value
Cases (n = 500) Controls (n = 504)
rs10754339 A 753 (75.30) 808 (80.16)
G 247 (24.70) 200 (19.84) 1.325 (1.073-1.637) 0.009a
rs10801935 A 836 (83.60) 818 (81.15) Reference
C 164 (16.40) 190 (18.85) 0.845 (0.671-1.063) 0.150
rs3738414 G 812 (81.20) 757 (75.10) Reference
A 188 (18.80) 251 (24.90) 0.698 (0.564-0.864) 0.001b
aP = 0.036 and bP = 0.003 after correcting P-value for multiple testing with 10,000 permutations by Haploview program.
Abbreviations: CI = confidence interval; OR = odds ratio.
Table 4: B7-H4 haplotype frequencies in cases and controls
B7-H4 haplotype Freq. cases (n = 500) controls (n = 504) OR (95% CI) P-value
rs10754339 rs10801935 rs3738414
A A G 0.507 52.0% 49.5% Reference
A A A 0.173 14.5% 20.0% 0.689 (0.539-0.881) 0.003
G A G 0.112 13.7% 8.6% 1.511 (1.125-2.031) 0.006
A C G 0.090 8.3% 9.6% 0.821 (0.598-1.128) 0.224
G C G 0.073 7.2% 7.4% 0.934 (0.660-1.321) 0.698
G A A 0.032 3.4% 3.1% 1.052 (0.637-1.739) 0.842
Abbreviations: CI = confidence interval; OR = odds ratio.BMC Cancer 2009, 9:394 http://www.biomedcentral.com/1471-2407/9/394
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genetic polymorphisms provided a new approach to
investigate the etiology of such complex genetic diseases
[18]. Reports indicate that breast cancer susceptibility and
prediction can be influenced by the polymorphism of
cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene, which
encodes a classic molecule offering a co-inhibitory signal
to T cell activation [19]. Additionally, some other genes
encoding novel co-inhibitors, such as PD-1 and B and T
lymphocyte attenuator (BTLA), are attractive in case-control
studies, as candidate genes between the gene polymor-
phisms and the risk of diseases [20,21]. As another co-
inhibitory molecule investigated more recently, B7-H4
has shown a potential effect on tumors, by which tumors
may escape from an anti-tumor immune response. To
elaborate, B7-H4 protein is over expressed in several
malignant tumors while is little expressed in normal tis-
sues [6-8,10], and its high expression in breast cancer
decreased the number of TILs and prevented tumor cells
from undergoing apoptosis [6,7,11].
In our case-control study, we chose three potentially func-
tional polymorphisms of B7-H4, rs10754339,
rs10801935 and re3738414, and firstly detected their
association with the risk and prognosis of breast cancer in
Chinese Han women. The results indicate that some of the
alleles, genotypes and haplotypes of these three SNPs are
associated with the risk and prognosis of breast cancer,
which will be discussed below respectively. According to
our results, in rs10754339, women with the AG genotype
and G allele are likely to have an increased risk of breast
cancer (OR = 1.455, 95% CI 1.119-1.892; OR = 1.325,
95%CI 1.073-1.637, respectively), indicating that the
rs10754339 G allele maybe plays a risk role in breast can-
cer. It has been suggested that B7-H4 mRNA is widely dis-
tributed in lymphoid and nonlymphoid tissues. However,
the protein is rarely expressed in normal tissues but highly
expressed in many kinds of tumor tissues including breast
cancer [3,6-10]. Also, 3'-UTR can regulate gene expression
at many different levels, and cis-acting elements of 3'-UTR
mediate the stability, degradation, and subcellular locali-
zation of mRNA [12,22]. Therefore, rs10754339 located
on ESE may regulate the production of mRNA molecules
through above mechanism, and G allele may be associ-
ated with an increased expression of B7-H4 and then
influence the susceptibility of breast cancer. In addition,
most tissues contain two types of B7-H4 transcriptions
which are ~2.0 kb and ~800 bp. The larger one is major
and their difference is that the small one has 3'-UTR
spliced out partly [8]. Rs10754339 may also be involved
in the formation and expression of different types of B7-
H4 transcriptions.
In rs10801935, women with the CC genotype are likely to
have a decreased risk of breast cancer (OR = 0.328, 95%
CI 0.145-0.739), indicating that the rs10801935 CC gen-
otype in intron 1 may be a protective factor in breast can-
cer. As we know, human gene expression requires
transcription controls mediated by the presence of intron
sequences, especially, the first intron, which contains var-
ious regulatory elements and splicing control elements
[14,23]. Mutations occurring in introns can induce the
aberrant splicing due to the disruption of the splice site,
the splicing enhancers and silencers, or the alteration of
the pre-mRNA secondary structure, which results in trans-
lational prevention [16,24,25]. Supposed to change the
secondary structure of pre-mRNA, rs10801935 can possi-
bly influence B7-H4 translational efficiency by causing
deviant splicing, and CC genotype may down-regulate the
B7-H4 expression and decrease the breast cancer risk.
Our research also suggests that women with the AA geno-
type and the A allele in rs3738414 are less likely to have
breast cancer (OR = 0.412, 95% CI 0.203-0.835; OR =
0.698, 95% CI 0.564-0.864, respectively), indicating that
the A allele of rs3738414 may have a potentially protec-
tive effect on breast cancer. 5'-UTR, upon which a number
of DNA binding sites of regulatory factors exist, is impor-
tant for post-transcriptional modification and translation
efficiency [12]. Using Pupasview software [15], the
rs3738414 is supposed to be located on ESE, and the
mutation of rs3738414 perhaps changes the protein bind-
ing pattern, and further affects the B7-H4 expression.
Consequently, rs3738414 A allele may reduce the B7-H4
expression and decrease the susceptibility of breast cancer.
In addition, according to the analysis for the association
between B7-H4 gene polymorphisms and clinical presen-
tations, we found that the rs10754339 GG genotype was
significantly associated with lymph node metastasis and
PR status, and the G allele and the AG genotype were
respectively associated with lymph node metastasis and
ER status. However, the other two SNPs in our study were
found to be irrelevant to clinicopathologic features.
Lymph node involvement, ER and PR status are important
in predicting the long-term survival of breast cancer cases.
Lymph node metastasis positive cases have higher mortal-
ity [26], and steroid hormone receptors are valuable as
predictive markers of endocrine therapy [27]. Therefore,
rs10754339 may be significant to forecast the prognosis
of breast cancer.
The association between B7-H4 gene and breast cancer
was further confirmed by the analysis of haplotype.
Results suggested that the AAA haplotype showed a signif-
icantly decreased risk of breast cancer, whereas GAG hap-
lotype had a contrary outcome (OR = 0.689, 95% CI
0.539-0.881; OR = 1.511, 95% CI 1.125-2.031). To elab-
orate, the AAA haplotype appears to be a protective factor
in breast cancer, but the GAG haplotype may be a risk fac-
tor in breast cancer. Furthermore, we found that both AAABMC Cancer 2009, 9:394 http://www.biomedcentral.com/1471-2407/9/394
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and GCG haplotypes had significantly correlations with
the clinical presentations. These haplotypes may also be
the valuable prognostic factors for survival of breast can-
cer cases.
Conclusion
It was observed in our study that polymorphisms of the
B7-H4 gene may affect the individual breast cancer risk
and prognosis in Chinese Han women, which provides
the first evidence for the involvement of the human B7-
H4 gene in breast cancer. The variants of rs10754339,
rs10801935 and rs3738414 are probably involved in the
risk of breast cancer. Furthermore, rs10754339 may par-
ticipate in the prognosis of breast cancer. AAA and GAG
haplotypes probably influence on the breast cancer risk,
and AAA and GCG may participate in the progression of
breast cancer. However, studies focusing on new polymor-
phisms with more samples from other populations as well
as the investigation of the basic functions of B7-H4 gene
mutations remain to be further conducted.
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